Global Biologic Therapeutics Market 2014-2018

生物学的製剤の世界市場:タンパク質治療薬、ワクチン、細胞治療薬

◆タイトル:Global Biologic Therapeutics Market 2014-2018
◆商品コード:IRTNTR4486
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年10月29日
◆ページ数:185
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD3,500 ⇒換算¥392,000見積依頼/購入/質問フォーム
Five UserUSD3,800 ⇒換算¥425,600見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD4,500 ⇒換算¥504,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"生物学的製剤の世界市場:タンパク質治療薬、ワクチン、細胞治療薬"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、需要先別分析、主要地域別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、主要企業(ベンダー)分析等の情報をお届けいたします。

About Biologic Therapeutics
Biologic therapeutics include virus, therapeutic serum, toxin, allergenic product, antitoxin, blood component or derivative, vaccine, blood, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), intended for the prevention, treatment, or cure of a disease or condition. These products differ from small molecules in terms of molecular weight, structure, synthesis, and immunogenicity. Biologic products are generally characterized by high molecular weight and complex structures. These products are usually derived from living entities and are less easily characterized compared to small molecules. These products are often susceptible to extreme temperatures and light.

TechNavio’s analysts forecast the Global Biologic Therapeutics market to grow at a CAGR of 8.22 percent over the period 2013-2018.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Biologic Therapeutics market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of the following drugs:
• Protein therapeutics (monoclonal antibodies, enzymes, and other protein therapeutics)
• Vaccines (pediatric vaccines and adult vaccines)
• Cell therapy

The Other Protein Therapeutics segment covers proteins such as cytokines, fusion proteins, peptide antibiotics, peptide hormones, and blood factors.
TechNavio’s report, Global Biologic Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Biologic Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Amgen
• F. Hoffmann-La Roche
• Novo Nordisk
• Sanofi

[Other Prominent Vendors]• Abbvie
• AstraZeneca
• Bavarian Nordic
• Baxter International
• Beijing Minhai Biotechnology
• Bharat Biotech
• Bharat Immunologicals and Biologicals
• bioCSL
• Biodel
• Bio Med
• Bristol-Myers Squibb
• Diamyd Medical
• DiaVacs
• Dynavax Technologies
• Eli Lilly
• Generex Biotechnology
• Hualan Biological Engineering
• Imunoloski Zavod
• Indian Immunologicals
• Janssen Pharmaceuticals
• JN International Medical
• Kaketsuken
• LG Life Sciences
• Macrogenics
• MannKind
• Merck & Co.
• Mitsubishi Tanabe Pharma
• Nuron Biotech
• Osiris Therapeutics
• Pfizer
• Protalix
• Protein Sciences
• Serum Institute of India
• Shenzhen Kangtai Biological Products
• Sinovac Biotech
• Tolerion
• Vacunas Finlay
• XOMA
• Zydus Cadila

[Market Driver]
• Aging Population
• For a full, detailed list, view our report

[Market Challenge]
• Requirement of Cold Storage
• For a full, detailed list, view our report

[Market Trend]
• Emergence of Targeted and Combination Therapies
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Molecule Type
08. Geographical Segmentation
09. Buying Criteria
10. Global Protein Therapeutics Market
10.1 Introduction
10.2 Drivers, Challenges and Trends
10.3 Market Size and Forecast
10.4 Market Segmentation by Molecule Type
10.4.1 Global Monoclonal Antibodies Market
10.4.2 Global Enzymes Market
10.4.3 Global Other Protein Therapeutics Market
11. Global Vaccines Market
11.1 Introduction
11.2 Drivers, Challenges and Trends
11.3 Market Size and Forecast
11.4 Market Segmentation by Composition
11.5 Market Segmentation by End-user Age Group
11.5.1 Global Pediatric Vaccines Market
11.5.2 Global Adult Vaccines Market
12. Global Cell Therapy Market
12.1 Introduction
12.2 Drivers, Challenges and Trends
12.3 Market Size and Forecast
13. Market Growth Drivers
13.1.1 Overall Market Drivers
13.1.2 Segment Specific Drivers
14. Drivers and their Impact
15. Market Challenges
15.1.1 Overall Market Challenges
15.1.2 Segment Specific Challenges
16. Impact of Drivers and Challenges
17. Market Trends
17.1.1 Overall Market Trends
17.1.2 Segment Specific Trends
18. Trends and their Impact
19. Competitive Scenario
19.1 Key News
19.2 Mergers and Acquisitions
20. Market Share Analysis 2013
20.1 Market Snapshot of Top Vendors
20.2 Market Share of Key Vendors
20.3 Market Forecast of Key Vendors
20.3.1 F. Hoffmann-La Roche
20.3.2 Sanofi
20.3.3 Amgen
20.3.4 Novo Nordisk
21. Market Assessment of Major Biologic Therapeutics of Key Vendors
21.1 F. Hoffmann-La Roche
21.1.1 Avastin
21.1.2 Herceptin
21.1.3 Kadcyla
21.1.4 Lucentis
21.1.5 MabThera/Rituxan
21.1.6 Pegasys
21.1.7 Perjeta
21.2 Sanofi
21.2.1 Aldurazyme
21.2.2 Cerezyme
21.2.3 Fabrazyme
21.2.4 Myozyme/Lumizyme
21.2.5 Lantus
21.3 Amgen
21.3.1 Enbrel
21.3.2 Neulasta
21.3.3 Xgeva/Prolia
21.4 Novo Nordisk
21.4.1 NovoRapid/NovoLog
21.4.2 Victoza
21.5 Other Prominent and Future Vendors
22. Key Vendor Analysis
22.1 Amgen
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Product Segmentation by Revenue 2013
22.1.4 Sales by Geographical Segmentation 2013
22.1.5 Business Strategy
22.1.6 Key Information
22.1.7 SWOT Analysis
22.2 F. Hoffmann-La Roche
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation
22.2.4 Business Segmentation by Revenue 2012 and 2013
22.2.5 Geographical Segmentation by Revenue
22.2.6 Business Strategy
22.2.7 Key Information
22.2.8 SWOT Analysis
22.3 Novo Nordisk A/S
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Business Segmentation
22.3.4 Business Strategy
22.3.5 Revenue Segmentation by Business
22.3.6 Revenue Comparison by Business Segments 2012 and 2013
22.3.7 Sales by Geography
22.3.8 Key Information
22.3.9 SWOT Analysis
22.4 Sanofi
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Segmentation by Revenue 2013
22.4.4 Business Segmentation by Revenue 2012 and 2013
22.4.5 Geographical Segmentation by Revenue 2013
22.4.6 Business Strategy
22.4.7 Key Developments
22.4.8 SWOT Analysis
23. Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Global Biologic Therapeutics Market 2013-2018 (US$ billion)
Exhibit 3: Global Biologic Therapeutics Market Segmentation by Molecule Type
Exhibit 4: Global Biologic Therapeutics Market by Molecule Type 2013
Exhibit 5: Global Biologic Therapeutics Market by Molecule Type 2018
Exhibit 6: Global Biologic Therapeutics Market by Molecule Type 2013-2018 (US$ billion)
Exhibit 7: Global Biologic Therapeutics Market by Molecule Type 2013-2018
Exhibit 8: Global Biologic Therapeutics Market Segments 2013-2018
Exhibit 9: YoY Growth Rate of Global Biologic Therapeutics Market Segments 2013-2018
Exhibit 10: Global Biologic Therapeutics Market Segmentation by Geography 2013
Exhibit 11: Key Factors Influencing the Global Protein Therapeutics Market
Exhibit 12: Global Protein Therapeutics Market Key Trends
Exhibit 13: Global Protein Therapeutics Market 2013-2018 (US$ billion)
Exhibit 14: Global Protein Therapeutics Market by Molecule Type
Exhibit 15: Global Protein Therapeutics Market by Molecule Type 2013
Exhibit 16: Global Protein Therapeutics Market by Molecule Type 2018
Exhibit 17: Global Protein Therapeutics Market by Molecule Type 2013-2018 (US$ billion)
Exhibit 18: Global Protein Therapeutics Market by Molecule Type 2013-2018
Exhibit 19: Global Protein Therapeutics Market Segmentation 2013-2018
Exhibit 20: YoY Growth Rate of Global Protein Therapeutics Market Segments 2013-2018
Exhibit 21: Global Monoclonal Antibodies Market 2013-2018 (US$ billion)
Exhibit 22: Global Enzymes Market 2013-2018 (US$ billion)
Exhibit 23: Global Other Protein Therapeutics Market 2013-2018 (US$ billion)
Exhibit 24: Global Vaccines Market Drivers
Exhibit 25: Global Vaccines Market Challenges
Exhibit 26: Global Vaccines Market Trends
Exhibit 27: Global Vaccines Market 2013-2018 (US$ billion)
Exhibit 28: Global Vaccines Market Segmentation by Vaccine Type
Exhibit 29: Global Vaccines Market Segmentation by End-user Age Group
Exhibit 30: Global Vaccines Market Segmentation by End-user Age Group 2013
Exhibit 31: Global Vaccines Market Segmentation by End-user Age Group 2018
Exhibit 32: Global Vaccines Market Segmentation by End-user Age Group 2013-2018 (US$ billion)
Exhibit 33: Global Vaccines Market Segmentation by End-user Age Group 2013-2018
Exhibit 34: Global Vaccines Market Segmentation 2013-2018
Exhibit 35: YoY Growth Rate of Global Vaccines Market Segments 2013-2018
Exhibit 36: Global Pediatric Vaccines Market 2013-2018 (US$ billion)
Exhibit 37: Global Adult Vaccines Market 2013-2018 (US$ billion)
Exhibit 38: Key Factors Influencing the Global Cell Therapy Market
Exhibit 39: Global Cell Therapy Market 2013-2018 (US$ billion)
Exhibit 40: Global Biologic Therapeutics Market Drivers
Exhibit 41: Global Biologic Therapeutics Overall Market Drivers
Exhibit 42: World’s Population Aged 60 and Above 2010-2020 (billion)
Exhibit 43: Global Biologic Therapeutics Segment Specific Drivers
Exhibit 44: Incidence and Prevalence of Type 1 Diabetes in Children (0-14 Years) 2013 (in thousands)
Exhibit 45: Global Biologic Therapeutics Market Challenges
Exhibit 46: Global Biologic Therapeutics Overall Market Challenges
Exhibit 47: Global Biologic Therapeutics Segment Specific Challenges
Exhibit 48: Global Biologic Therapeutics Market Trends
Exhibit 49: Global Biologic Therapeutics Market General Trends
Exhibit 50: Global Biologic Therapeutics Segment Specific Trends
Exhibit 51: Market Statistics for Key Vendors in Global Biologic Therapeutics Market
Exhibit 52: Global Biologic Therapeutics Market Share Analysis 2013
Exhibit 53: Global Biologic Therapeutics Market Share Analysis 2018
Exhibit 54: Global Biologic Therapeutics Market Share Analysis of Key Vendors 2013
Exhibit 55: Global Biologic Therapeutics Market Share Analysis of Key Vendors 2018
Exhibit 56: YoY Growth Rate of Key Vendors in the Global Biologic Therapeutics Market
Exhibit 57: F. Hoffmann-La Roche Biologic Therapeutics Market Size and Forecast 2013-2018 (US$ billion)
Exhibit 58: Sanofi Biologic Therapeutics Market Size and Forecast 2013-2018 (US$ billion)
Exhibit 59: Amgen Biologic Therapeutics Market Size and Forecast 2013-2018 (US$ billion)
Exhibit 60: Novo Nordisk Biologic Therapeutics Market Size and Forecast 2013-2018 (US$ billion)
Exhibit 61: Revenue of Major Biologic Therapeutics of Key Vendors
Exhibit 62: F. Hoffmann-La Roche: Market Sales for Key Biologic Therapeutics 2013 (US$ million)
Exhibit 63: Geography-wise Segmentation of Avastin 2013 (US$ million)
Exhibit 64: Geography-wise Segmentation of Avastin 2013
Exhibit 65: Avastin Market Size and Forecast 2013-2018 (US$ million)
Exhibit 66: Geography-wise Segmentation of Herceptin 2013 (US$ million)
Exhibit 67: Geography-wise Segmentation of Herceptin 2013
Exhibit 68: Herceptin Market Size and Forecast 2013-2018 (US$ million)
Exhibit 69: Geography-wise Segmentation of Kadcyla 2013 (US$ million)
Exhibit 70: Geography-wise Segmentation of Kadcyla 2013
Exhibit 71: Kadcyla Market Size and Forecast 2013-2018 (US$ million)
Exhibit 72: Timeline of Key Regulatory Approvals of Lucentis
Exhibit 73: Lucentis Sales by Geographical Segmentation 2006-2013 (US$ million)
Exhibit 74: Lucentis Revenue 2006-2013 (US$ million)
Exhibit 75: Geography-wise Segmentation of MabThera/Rituxan 2013 (US$ million)
Exhibit 76: Geography-wise Segmentation of MabThera/Rituxan 2013
Exhibit 77: MabThera/Rituxan Market Size and Forecast 2013-2018 (US$ million)
Exhibit 78: Geography-wise Segmentation of Pegasys 2013 (US$ million)
Exhibit 79: Geography-wise Segmentation of Pegasys 2013
Exhibit 80: Geography-wise Segmentation of Perjeta 2013 (US$ million)
Exhibit 81: Geography-wise Segmentation of Perjeta 2013
Exhibit 82: Perjeta Market Size and Forecast 2013-2018 (US$ million)
Exhibit 83: SanofI: Market Sales for Key Biologic Therapeutics 2013 (US$ million)
Exhibit 84: Geography-wise Segmentation of Aldurazyme 2013 (US$ million)
Exhibit 85: Geography-wise Segmentation of Aldurazyme 2013
Exhibit 86: Geography-wise Segmentation of Cerezyme 2013 (US$ million)
Exhibit 87: Geography-wise Segmentation of Cerezyme 2013
Exhibit 88: Geography-wise Segmentation of Fabrazyme 2013 (US$ million)
Exhibit 89: Geography-wise Segmentation of Fabrazyme 2013
Exhibit 90: Geography-wise Segmentation of Myozyme/Lumizyme 2013 (US$ million)
Exhibit 91: Geography-wise Segmentation of Myozyme/Lumizyme 2013
Exhibit 92: Geography-wise Segmentation of Lantus 2013 (US$ million)
Exhibit 93: Geography-wise Segmentation of Lantus 2013
Exhibit 94: Lantus Market Size and Forecast 2013-2018 (US$ million)
Exhibit 95: Geography-wise Segmentation of Enbrel 2013 (US$ million)
Exhibit 96: Geography-wise Segmentation of Enbrel 2013
Exhibit 97: Enbrel Market Size and Forecast 2013-2018 (US$ million)
Exhibit 98: Geography-wise Segmentation of Neulasta 2013 (US$ million)
Exhibit 99: Geography-wise Segmentation of Neulasta 2013
Exhibit 100: Neulasta Market Size and Forecast 2013-2018 (US$ million)
Exhibit 101: Geography-wise Segmentation of Xgeva/Prolia 2013 (US$ million)
Exhibit 102: Geography-wise Segmentation of Xgeva/Prolia 2013
Exhibit 103: Xgeva/Prolia Market Size and Forecast 2013-2018 (US$ million)
Exhibit 104: Market Sales for Key Biologic Therapeutics 2013 (US$ million)
Exhibit 105: Geography-wise Sales for Key Biologic Therapeutics 2013 (US$ million)
Exhibit 106: Geography-wise Segmentation of NovoRapid/NovoLog 2013 (US$ million)
Exhibit 107: Geography-wise Segmentation of NovoRapid/NovoLog 2013
Exhibit 108: NovoRapid/NovoLog Market Size and Forecast 2013-2018 (US$ million)
Exhibit 109: Geography-wise Segmentation of Victoza 2013 (US$ million)
Exhibit 110: Geography-wise Segmentation of Victoza 2013
Exhibit 111: Victoza Market Size and Forecast 2013-2018 (US$ million)
Exhibit 112: Amgen: Product Segmentation by Revenue 2013
Exhibit 113: Amgen: Sales by Geographical Segmentation 2013
Exhibit 114: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 115: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 116: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
Exhibit 117: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
Exhibit 118: Business Segments of Novo Nordisk A/S 2013
Exhibit 119: Novo Nordisk A/S: Business Segmentation 2013
Exhibit 120: Novo Nordisk A/S: Revenue Comparison 2012 and 2013 (US$ million)
Exhibit 121: Novo Nordisk A/S: Sales by Geography 2013
Exhibit 122: Sanofi: Business Segmentation by Revenue 2013
Exhibit 123: Sanofi: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 124: Sanofi: Geographical Segmentation by Revenue 2013



【掲載企業】

Amgen, F. Hoffmann-La Roche, Novo Nordisk, Sanofi, Abbvie, AstraZeneca, Bavarian Nordic, Baxter International, Beijing Minhai Biotechnology, Bharat Biotech, Bharat Immunologicals and Biologicals , bioCSL, Biodel , Bio Med, Bristol-Myers Squibb, Diamyd Medical ,DiaVacs , Dynavax Technologies, Eli Lilly, Generex Biotechnology, Hualan Biological Engineering, Imunoloski Zavod, Indian Immunologicals, Janssen Pharmaceuticals, JN International Medical, Kaketsuken, LG Life Sciences, Macrogenics , MannKind , Merck & Co. ,Mitsubishi Tanabe Pharma, Nuron Biotech, Osiris Therapeutics , Pfizer, Protalix, Protein Sciences , Serum Institute of India, Shenzhen Kangtai Biological Products , Sinovac Biotech, Tolerion , Vacunas Finlay, XOMA, Zydus Cadila

【資料のキーワード】

生物学的製剤、タンパク質治療薬、ワクチン、細胞治療薬、モノクローナル抗体、酵素

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[生物学的製剤の世界市場:タンパク質治療薬、ワクチン、細胞治療薬]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆